Interleukin-4 and its alternatively spliced variant (IL-4δ2) in patients with atopic asthma

Geok Teng Seah, Peisong Gao, Julian M. Hopkin, Graham A W Rook

Research output: Contribution to journalArticle

Abstract

The interleukin-4 (IL-4) splice variant (IL-4δ2) is known to antagonize many biological activities of IL-4, and this challenges our understanding of the role of IL-4 in asthma. Studies that have used nonspecific antibodies, probes, and/or primers to quantify IL-4 in clinical samples would not have distinguished the expression of IL-4 from IL-4δ2. This is the first study to examine patients with chronic asthma and atopy for IL-4δ2 mRNA in their peripheral blood mononuclear cells without antigen stimulation, using a quantitative nested reverse-transcription polymerase chain reaction (RT-PCR) protocol. The median IL-4 mRNA copy number in cells from the patients with asthma was 2.8 logs higher than in a comparator group of patients with tuberculosis (p = 0.0005) and 4.5 logs higher (p = 0.0004) than in healthy control subjects. In contrast, IL-4δ2 expression in cells from patients with asthma was similar to that seen in cells from patients with tuberculosis. Hence, the median ratio of IL-4 to IL-4δ2 was 500-fold higher in the patients with asthma when compared with either patients with tuberculosis or healthy control subjects. The relative expression of IL-4 and IL-4δ2 may be a reason for the functional diversity of Th2 cells in different clinical conditions, and a hitherto unexplored mechanism for the pulmonary pathology in patients with atopic asthma.

Original languageEnglish (US)
Pages (from-to)1016-1018
Number of pages3
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume164
Issue number6
StatePublished - Sep 15 2001
Externally publishedYes

Fingerprint

Interleukin-4
Asthma
Tuberculosis
Healthy Volunteers
Th2 Cells
Messenger RNA
Reverse Transcription
Blood Cells
Cell Count
Pathology
Antigens
Polymerase Chain Reaction
Lung
Antibodies

Keywords

  • Asthma
  • Atopy
  • Interleukin-4
  • Splice variant

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Interleukin-4 and its alternatively spliced variant (IL-4δ2) in patients with atopic asthma. / Seah, Geok Teng; Gao, Peisong; Hopkin, Julian M.; Rook, Graham A W.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 164, No. 6, 15.09.2001, p. 1016-1018.

Research output: Contribution to journalArticle

@article{dc7bd23e4d0d433c8769bb12dda019cb,
title = "Interleukin-4 and its alternatively spliced variant (IL-4δ2) in patients with atopic asthma",
abstract = "The interleukin-4 (IL-4) splice variant (IL-4δ2) is known to antagonize many biological activities of IL-4, and this challenges our understanding of the role of IL-4 in asthma. Studies that have used nonspecific antibodies, probes, and/or primers to quantify IL-4 in clinical samples would not have distinguished the expression of IL-4 from IL-4δ2. This is the first study to examine patients with chronic asthma and atopy for IL-4δ2 mRNA in their peripheral blood mononuclear cells without antigen stimulation, using a quantitative nested reverse-transcription polymerase chain reaction (RT-PCR) protocol. The median IL-4 mRNA copy number in cells from the patients with asthma was 2.8 logs higher than in a comparator group of patients with tuberculosis (p = 0.0005) and 4.5 logs higher (p = 0.0004) than in healthy control subjects. In contrast, IL-4δ2 expression in cells from patients with asthma was similar to that seen in cells from patients with tuberculosis. Hence, the median ratio of IL-4 to IL-4δ2 was 500-fold higher in the patients with asthma when compared with either patients with tuberculosis or healthy control subjects. The relative expression of IL-4 and IL-4δ2 may be a reason for the functional diversity of Th2 cells in different clinical conditions, and a hitherto unexplored mechanism for the pulmonary pathology in patients with atopic asthma.",
keywords = "Asthma, Atopy, Interleukin-4, Splice variant",
author = "Seah, {Geok Teng} and Peisong Gao and Hopkin, {Julian M.} and Rook, {Graham A W}",
year = "2001",
month = "9",
day = "15",
language = "English (US)",
volume = "164",
pages = "1016--1018",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "6",

}

TY - JOUR

T1 - Interleukin-4 and its alternatively spliced variant (IL-4δ2) in patients with atopic asthma

AU - Seah, Geok Teng

AU - Gao, Peisong

AU - Hopkin, Julian M.

AU - Rook, Graham A W

PY - 2001/9/15

Y1 - 2001/9/15

N2 - The interleukin-4 (IL-4) splice variant (IL-4δ2) is known to antagonize many biological activities of IL-4, and this challenges our understanding of the role of IL-4 in asthma. Studies that have used nonspecific antibodies, probes, and/or primers to quantify IL-4 in clinical samples would not have distinguished the expression of IL-4 from IL-4δ2. This is the first study to examine patients with chronic asthma and atopy for IL-4δ2 mRNA in their peripheral blood mononuclear cells without antigen stimulation, using a quantitative nested reverse-transcription polymerase chain reaction (RT-PCR) protocol. The median IL-4 mRNA copy number in cells from the patients with asthma was 2.8 logs higher than in a comparator group of patients with tuberculosis (p = 0.0005) and 4.5 logs higher (p = 0.0004) than in healthy control subjects. In contrast, IL-4δ2 expression in cells from patients with asthma was similar to that seen in cells from patients with tuberculosis. Hence, the median ratio of IL-4 to IL-4δ2 was 500-fold higher in the patients with asthma when compared with either patients with tuberculosis or healthy control subjects. The relative expression of IL-4 and IL-4δ2 may be a reason for the functional diversity of Th2 cells in different clinical conditions, and a hitherto unexplored mechanism for the pulmonary pathology in patients with atopic asthma.

AB - The interleukin-4 (IL-4) splice variant (IL-4δ2) is known to antagonize many biological activities of IL-4, and this challenges our understanding of the role of IL-4 in asthma. Studies that have used nonspecific antibodies, probes, and/or primers to quantify IL-4 in clinical samples would not have distinguished the expression of IL-4 from IL-4δ2. This is the first study to examine patients with chronic asthma and atopy for IL-4δ2 mRNA in their peripheral blood mononuclear cells without antigen stimulation, using a quantitative nested reverse-transcription polymerase chain reaction (RT-PCR) protocol. The median IL-4 mRNA copy number in cells from the patients with asthma was 2.8 logs higher than in a comparator group of patients with tuberculosis (p = 0.0005) and 4.5 logs higher (p = 0.0004) than in healthy control subjects. In contrast, IL-4δ2 expression in cells from patients with asthma was similar to that seen in cells from patients with tuberculosis. Hence, the median ratio of IL-4 to IL-4δ2 was 500-fold higher in the patients with asthma when compared with either patients with tuberculosis or healthy control subjects. The relative expression of IL-4 and IL-4δ2 may be a reason for the functional diversity of Th2 cells in different clinical conditions, and a hitherto unexplored mechanism for the pulmonary pathology in patients with atopic asthma.

KW - Asthma

KW - Atopy

KW - Interleukin-4

KW - Splice variant

UR - http://www.scopus.com/inward/record.url?scp=0035883732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035883732&partnerID=8YFLogxK

M3 - Article

VL - 164

SP - 1016

EP - 1018

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 6

ER -